<!DOCTYPE html><!-- Last Published: Tue Mar 16 2021 05:49:37 GMT+0000 (Coordinated Universal Time) -->
<html data-wf-domain="www.breastacncerawarenessgero310.com" data-wf-page="5fcf3de6a4cc4082f2b959b1"
    data-wf-site="5fcccfe2fca8cbf4ccf3e2f1">

<head>
    <meta charset="utf-8" />
    <title>OUR TREATMENTS</title>
    <meta content="Majestyk Apps" property="og:title" />
    <meta content="Majestyk Apps" property="twitter:title" />
    <meta content="width=device-width, initial-scale=1" name="viewport" />
    <link href="styles.css" rel="stylesheet" type="text/css" />
    <script src="https://ajax.googleapis.com/ajax/libs/webfont/1.6.26/webfont.js" type="text/javascript"></script>
    <script
        type="text/javascript">WebFont.load({ google: { families: ["Lato:100,100italic,300,300italic,400,400italic,700,700italic,900,900italic", "Droid Sans:400,700", "Varela Round:400", "Roboto:100italic,300,300italic,regular,italic,500,500italic,700,700italic,900,900italic:vietnamese,cyrillic-ext,greek-ext,greek,latin-ext,latin,cyrillic"] } });</script>
    <!--[if lt IE 9]><script src="https://cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv.min.js" type="text/javascript"></script><![endif]-->
    <script
        type="text/javascript">!function (o, c) { var n = c.documentElement, t = " w-mod-"; n.className += t + "js", ("ontouchstart" in o || o.DocumentTouch && c instanceof DocumentTouch) && (n.className += t + "touch") }(window, document);</script>
    <link href="MS-BRAIN.png"
        rel="shortcut icon" type="image/x-icon" />
    <link href="MS-BRAIN.png"
        rel="apple-touch-icon" />
</head>

<body>
    <div data-collapse="none" data-animation="default" data-duration="400" role="banner" class="navbar w-nav"><a
            href="index.html" class="brand w-nav-brand"><img src="ms-nerve.png"
                width="230" sizes="(max-width: 479px) 13vw, (max-width: 767px) 47px, 65.796875px"
                srcset="ms-nerve.png 500w, ms-nerve.png 800w, ms-nerve.png 1080w, ms-nerve.png 1600w, ms-nerve.png 2000w, ms-nerve.png 2600w, ms-nerve.png 3200w, ms-nerve.png 4756w"
                alt="" class="image-9" /></a>
                <nav role="navigation" class="nav-menu w-nav-menu"><a href="about.html" class="link-nav w-nav-link">ABOUT US</a><a
                    href="ourtreatment.html" class="link-nav w-nav-link">OUR TREATMENTS</a><a href="research.html" aria-current="page"
                    class="link-nav w-nav-link w--current">RESEARCH</a>
                    <a href="clinicaltrials.html" class="link-nav w-nav-link">CLINICAL TRIALS</a>
                </nav>
        <div class="w-nav-button">
            <div class="w-icon-nav-menu"></div>
        </div>
    </div>

    <div class="div-block-majestyk-69"></div>
    <div class="container-3 w-container">
        <div data-w-id="43a4528a-e2a5-5c2c-849f-808477ada91a" style="opacity:0" class="columns-2 w-row">
            <div class="w-col w-col-6">
                <h1 class="heading-12 heading-14">Treating MS </h1>
            </div>
            <div class="w-col w-col-6">
                <h1 class="heading-13">The FDA approved Bristol Myers Squibb's ozanimod (Zeposia) 0.92 mg as an oral treatment for relapsing forms of multiple sclerosis (RMS).</h1>
            </div>
        </div>
        <div data-w-id="43a4528a-e2a5-5c2c-849f-808477ada921" style="opacity:0" class="columns-3 w-row">
            <div class="w-col w-col-4">
                <div class="text-block-4"><span class="text-span-3">ABOUT ZEPOSIA</span><br /><br />Zeposia is a selective sphingosine 1-phosphate receptor modulator. It is thought to act by promoting the retention of certain white blood cells in the bodyâ€™s lymph nodes, keeping them out of circulation and from entering the brain and spinal cord.  </div>
            </div>
            <div class="w-col w-col-4">
                <div class="text-block-5"><span class="text-span-4">POTENTIAL BENEFITS<br /></span><br /><span
                        class="text-span-6">Two phase 3 clinical trials, involving more than 2,600 people with relapsing MS, compared two different doses of daily oral Zeposia to Avonex (injected into the muscle once weekly). Zeposia was found to significantly reduce annual relapse rates, and reduced new MRI-detected signs of disease activity. </span></div>
            </div>
            <div class="w-col w-col-4">
                <div class="text-block-6"><span class="text-span-5">POTENTIAL RISK<br /></span><br />The most common adverse reactions reported from clinical trials were upper respiratory infection, increases in liver function tests, low blood pressure after standing up (orthostatic hypotension), urinary tract infection, back pain, and high blood pressure. 


                </div>
            </div>
        </div><img
            src="https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111.png"
            loading="lazy" sizes="(max-width: 479px) 83vw, (max-width: 767px) 84vw, (max-width: 991px) 648px, 940px"
            srcset="https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111-p-800.png 800w, https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111-p-1080.png 1080w, https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111-p-1600.png 1600w, https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111-p-2000.png 2000w, https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111-p-2600.png 2600w, https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111-p-3200.png 3200w, https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/5fcf2c67c512d42bc7eccc83_Line%20111.png 8360w"
            alt="" class="image-25" />
        <div data-w-id="43a4528a-e2a5-5c2c-849f-808477ada93c" style="opacity:0" class="w-row">
            <div class="w-col w-col-4">
                <h1 class="heading-23">Q&A:</h1>
            </div>
            <div class="w-col w-col-8">
                <div class="text-block-8">Q:Why should a person with MS consider taking a disease-modifying therapy?
                    <br /><br /> +Taking a disease-modifying therapy is currently the best way to reduce MS disease activity and future deterioration. Studies comparing people in clinical trials who started therapy earlier than those on inactive placebo suggest that early treatment offered important benefits against the accumulation of disability, which were generally not experienced to the same degree by those who started treatment later.
                    <br /><br /> Q:When will Zeposia become available?
                    <br /><br /> As of June 1, 2020, Bristol Myers Squibb has announced that Zeposia is ready to be prescribed.
                    <br /><br />What will Zeposia cost?
                    <br /><br />+The list price of Zeposia has been announced as $86,000 per year. The actual cost to an individual who has MS will depend on the provisions of his or her insurance coverage and the degree to which that individual will be eligible for programs designed to assist with out-of-pocket costs.
                </div>
            </div>
        </div>
        <div class="w-col w-col-8">
            
            
            <script
                src="https://d3e54v103j8qbb.cloudfront.net/js/jquery-3.5.1.min.dc5e7f18c8.js?site=5fcccfe2fca8cbf4ccf3e2f1"
                type="text/javascript" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0="
                crossorigin="anonymous"></script>
            <script src="https://uploads-ssl.webflow.com/5fcccfe2fca8cbf4ccf3e2f1/js/webflow.c095b40f3.js"
                type="text/javascript"></script>
            <!--[if lte IE 9]><script src="//cdnjs.cloudflare.com/ajax/libs/placeholders/3.0.2/placeholders.min.js"></script><![endif]-->
</body>

</html